Das181 covid-19

Phase 3

Das181 covid-19 is one of 2 therapeutic programs targeting Lower Respiratory Tract Infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lower Respiratory Tract InfectionRecruiting

Lower Respiratory Tract InfectionPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Lower Respiratory Tract Infection

#DrugCompanyPhaseTrials

DAS181

AAnsun Biopharma, Inc.

Phase 3

1 2

Das181 covid-19

AAnsun Biopharma, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Lower Respiratory Tract Infection

NCT03808922

Clinical

Trials by Indication[1]

Lower Respiratory Tract Infection1 trial

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

Recruiting·AAnsun Biopharma, Inc.·Phase 3·NCT03808922·274 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Das181 covid-19. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Das181 covid-19. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ansun Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAnsun Biopharma, Inc.

Das181 covid-19

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Lower Respiratory Tract Infection1 trial

References

Drug Info

Quick Facts

Related News